While the potential of myelin-directed imaging probes for monitoring disease progression and response to therapy has been demonstrated, TSPO PET has shown initial encouraging results as a prognostic marker, which holds promise to improve clinical decision-making by allowing early clarification of the optimal therapeutic strategy, particularly for fast-progressing forms of MS. The gene discussed is TSPO; the disease is myeloid sarcoma.